Vectura receives milestone payment from Boehringer Ingleheim
This article was originally published in Scrip
Executive Summary
Vecturais to receive another €7.5 million milestone payment from Boehringer Ingelheimas part of the two companies' asthma and COPD deal. Vectura, which has been developing a multi-dose dry powder inhaler to deliver Boehringer Ingelheim's respiratory disease products, previously received licensing and milestone payments of €20 million and a €10 million equity investment from the German company. Though no details on what the milestone was connected to were released, Piper Jaffray analysts speculated that it was triggered by progress in the development of a drug/ device combination. The analysts added that the milestone is another sign that the collaboration is progressing well and that it should aid negotiations between Vectura and third parties that the company may wish to license its products to. Vectura could receive further milestones that could be up to €20 million for each drug that is approved, Piper Jaffray said. The UK company will also receive royalties on global sales of Boehringer Ingelheim products delivered using the inhaler.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.